Adrenaclick is a drug owned by Impax Laboratories Llc. It is protected by 4 US drug patents filed from 2013 to 2020. Out of these, 3 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 12, 2027. Details of Adrenaclick's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7905352 | Kits containing medicine injection devices and containers |
Apr, 2027
(2 years from now) | Active |
| US10166334 | Medicine injection apparatuses |
Jan, 2025
(a month from now) | Active |
| US10166344 | Injection needle assembly |
Jan, 2025
(a month from now) | Active |
| US5665071 | Reloadable automatic or manual emergency injection system |
May, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Adrenaclick's patents.
Latest Legal Activities on Adrenaclick's Patents
Given below is the list of recent legal activities going on the following patents of Adrenaclick.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Aug, 2022 | US7905352 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Jun, 2022 | US10166344 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 31 May, 2022 | US10166334 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 30 Jan, 2019 | US7905352 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Jan, 2019 | US7905352 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Jan, 2019 | US10166344 |
| Recordation of Patent Grant Mailed Critical | 01 Jan, 2019 | US10166344 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Jan, 2019 | US10166334 |
| Recordation of Patent Grant Mailed Critical | 01 Jan, 2019 | US10166334 |
| Issue Notification Mailed Critical | 12 Dec, 2018 | US10166334 |
US patents provide insights into the exclusivity only within the United States, but Adrenaclick is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Adrenaclick's family patents as well as insights into ongoing legal events on those patents.
Adrenaclick's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Adrenaclick's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 12, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Adrenaclick Generic API suppliers:
Epinephrine is the generic name for the brand Adrenaclick. 4 different companies have already filed for the generic of Adrenaclick, with Am Regent having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Adrenaclick's generic
Alternative Brands for Adrenaclick
There are several other brand drugs using the same active ingredient (Epinephrine) as Adrenaclick. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Adamis Pharms Corp |
| ||
| Armstrong Pharms |
| ||
| Ars Pharms Operation |
| ||
| Baxter Hlthcare Corp |
| ||
| Bpi Labs |
| ||
| Endo Operations |
| ||
| Impax |
| ||
| Inforlife |
| ||
| Kaleo Inc |
| ||
| Long Grove Pharms |
| ||
| Mylan Speciality Lp |
| ||
| Vyteris |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Epinephrine, Adrenaclick's active ingredient. Check the complete list of approved generic manufacturers for Adrenaclick
About Adrenaclick
Adrenaclick is a drug owned by Impax Laboratories Llc. Adrenaclick uses Epinephrine as an active ingredient. Adrenaclick was launched by Impax in 2009.
Approval Date:
Adrenaclick was approved by FDA for market use on 25 November, 2009.
Active Ingredient:
Adrenaclick uses Epinephrine as the active ingredient. Check out other Drugs and Companies using Epinephrine ingredient
Dosage:
Adrenaclick is available in injectable form for intramuscular, subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.3MG/DELIVERY | INJECTABLE | Prescription | INTRAMUSCULAR, SUBCUTANEOUS |
| EQ 0.15MG/DELIVERY | INJECTABLE | Prescription | INTRAMUSCULAR, SUBCUTANEOUS |